Susan McCloskey, MD, MSHS

Dr. Susan McCloskey's research focuses on quality of care, quality of life and health technology and outcomes assessment.

Fowble BL, Einck JP, Kim DN, McCloskey S, Mayadev J, Yashar C, Chen SL, Hwang ES. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):494-503.

Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011 Sep;12(10):933-80.

McCloskey SA, Lee SP, Steinberg ML. Roles and types of radiation in breast cancer treatment: early breast cancer, locoregionally advanced, and metastatic disease. Curr Opin Obstet Gynecol. 2011 Feb;23(1):51-7.

McCloskey SA, Tchabo NE, Malhotra HK, Odunsi K, Rodabaugh K, Singhal P, Lele S, Jaggernauth W. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol. 2010 Mar;116(3):404-7. Epub 2009 Nov 27

McCloskey SA, Jaggernauth W, Rigual NR, Hicks WL, Popat SR, Sullivan M, Mashtare TL, Khan MK, Loree TR, Singh AK. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009 Dec;32(6):587-91.